Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay
- 506 Downloads
Varicella is a highly contagious disease caused by primary infection of Varicella zoster virus (VZV). Varicella can be severe or even lethal in susceptible adults, immunocompromised patients and neonates. Determination of the status of immunity to VZV is recommended for these high-risk populations. Furthermore, measurement of population immunity to VZV can help in developing proper varicella vaccination programmes. VZV glycoprotein E (gE) is an antigen that has been demonstrated to be a highly accurate indicator of VZV-specific immunity. In this study, recombinant gE (rgE) was used to establish a double antigen sandwich enzyme-linked immunosorbent assay (ELISA). The established sandwich ELISA showed high specificity and sensitivity in the detection of human sera, and it could detect VZV-specific antibodies at a concentration of 11.25 m IU/mL with a detection linearity interval of 11.25 to 360 m IU/mL (R 2 = 0.9985). The double gE antigen sandwich ELISA showed a sensitivity of 95.08 % and specificity of 100 % compared to the fluorescent-antibody-to-membrane-antigen (FAMA) test, and it showed a sensitivity of 100 % and a specificity of 94.74 % compared to a commercial neutralizing antibody detection kit. Thus, the established double antigen sandwich ELISA can be used as a sensitive and specific quantitative method to evaluate immunity to VZV.
KeywordsDouble antigen sandwich ELISA Glycoprotein E Varicella zoster virus Serological evaluation
We thank members of the Analysis and Testing Centre (School of Life Sciences, Xiamen University) for their mass spectrometry work. Editors at NPG Language Editing provided editing assistance to the authors during the preparation of this manuscript.
Compliance with ethical standards
This work was supported by a grant from the National High Technology Research and Development Programme of China (No. 2012AA02A408) and the National Science and Technology Major Project of Infectious Diseases (No. 2012ZX10004503-005). The funding sources had no involvement in study design, data collection and decision for publication.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the Independent Ethics Committee approval obtained from the Ethics Committee of the National Institute of Diagnostics and Vaccine Development in Infectious Diseases.
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- Baiker A, Haase R, Eberle J, Vizoso Pinto MG, Pfrepper KI, Petrich A, Deml L, Campe H, Nitschko H, Jaeger G (2010) Early detection of varicella-zoster virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report. Virol J 7:54. doi: 10.1186/1743-422X-7-54
- Bourre B, Lefaucheur R, Ahtoy P, Travers F, Fetter D (2013) Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology 81(22):1966–1967. doi: 10.1212/01.wnl.0000439052.05262.1d
- Caunt AE, Shaw DG (1969) Neutralization tests with varicella-zoster virus. J Hyg (Lond) 67(2):343–352Google Scholar
- Davison AJ, Edson CM, Ellis RW, Forghani B, Gilden D, Grose C, Keller PM, Vafai A, Wroblewska Z, Yamanishi K (1986) New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol 57(3):1195–1197Google Scholar
- Hammond O, Wang Y, Green T, Antonello J, Kuhn R, Motley C, Stump P, Rich B, Chirmule N, Marchese RD (2006) The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 78(12):1679–1687. doi: 10.1002/jmv.20754 CrossRefPubMedGoogle Scholar
- Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW (1986) Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 14(2):177–188. doi: 10.1016/0166-0934(86)90048-0 CrossRefPubMedGoogle Scholar
- Liu J, Zhu R, Ye X, Yang L, Wang Y, Huang Y, Wu J, Wang W, Ye J, Li Y, Zhao Q, Zhu H, Cheng T, Xia N (2015) A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine. Appl Microbiol Biot 99(11):4545–4553. doi: 10.1007/s00253-015-6602-5 CrossRefGoogle Scholar
- Maple PA, Gray J, Breuer J, Kafatos G, Parker S, Brown D (2006) Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 13(2):214–218. doi: 10.1128/CVI.13.2.214-218.2006 CrossRefPubMedPubMedCentralGoogle Scholar
- Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119(1):25–30. doi: 10.1016/j.jviromet.2004.02.012 CrossRefPubMedGoogle Scholar
- Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P (2012) Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol 19(8):1261–1268. doi: 10.1128/CVI.00183-12 CrossRefPubMedPubMedCentralGoogle Scholar